Combinatorial prevention of carcinogenic risk in a model for familial colon cancer

Oncology Reports

Volumn 17, Issue 4, 2007, Pages 909-914

  Telang, Nitin ^a   Katdare, Meena ^b  

^a Department of Obstetrics Gynecology   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adenomatous polyposis coli mutation; Carcinogenic risk; Combinatorial prevention

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BIOLOGICAL MODEL; CELL PROLIFERATION; CELL TRANSFORMATION; CHEMOPROPHYLAXIS; COLON TUMOR; DRUG SCREENING; EVALUATION; HUMAN; PRECANCER; RISK;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHEMOPREVENTION; COLONIC NEOPLASMS; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, BIOLOGICAL; PRECANCEROUS CONDITIONS; RISK;

EID: 34147115611     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.4.909     Document Type: Article

References (46)

1. Jemal A, Murray T, Ward E, et al : Cancer Statistics-2006. Cancer J Clin 56: 106-130, 2006.
2. Abbruzzese JL and Lippman SM: The convergence of prevention and therapy in early phase clinical drug development. Cancer Cell 6: 321-326, 2004. (Pubitemid 39361433)
3. Hong WK and Sporn MB: Recent advances in chemoprevention of cancer. Science 278: 1073-1077, 1997. (Pubitemid 27517878)
4. Kelloff GJ, Lippman SM, Dannenberg AJ, et al: Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer, a plan to move forward. Clin Cancer Res 12: 3661-3697, 2006. (Pubitemid 44000248)
5. Fodde R, Smits R and Cleavers H: APC signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 1: 5-67, 2001.
6. Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61: 759-767, 1990.
7. Moser AR, Pitot HC and Dove WF: A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247: 322-324, 1990.
8. Su L-K, Kinzler KW, Vogelstein B, et al: Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256: 688-670, 1992.
9. Corbet DE and Pierre F: Point: From animal models to prevention of colon cancer. Systemic review of chemoprevention in Min mice and choice of the model system. Cancer Epid Biomark Prev 12: 391-400, 2003.
10. Minmice and human cancer patients. Cancer Res 64: 3694-3700, 2004.
11. Katdare M, Kopelovich L and Telang N: Efficacy of chemopreventive agents for growth inhibition of APC [+/-] 1638N COL colonic epithelial cells. Int J Mol Med 10: 427-432, 2002.
12. Telang NT, Li G and Katdare M: Prevention of early onset familial/hereditary colon cancer: New models and mechanistic biomarkers (Review). Int J Oncol 28: 1523-1529, 2006.
13. Katdare M, Osborne M and Telang N: Soy isoflavone genistein modulates cell cycle progression and induces apoptosis in HER-2/ neu oncogene expressing human breast epithelial cells. Int J Oncol 21: 809-815, 2002.
14. Katdare M, Osborne MP and Telang NT: Novel cell culture models for prevention of human breast cancer (Review). Int J Oncol 22: 509-515, 2003.
15. Telang NT, Narayanan R, Bradlow HL, et al : Co-ordinated expression of intermediate biomarkers for tumorigenic transformation of Ras-transfected mouse mammary epithelial cells. Breast Cancer Res Treat 18: 155-163, 1991.
16. Telang NT, Osborne MP, Sweterlitsch LA, et al: Neoplastic transformation of mouse mammary epithelial cells by deregulated myc expression. Cell Regul 1: 863-872, 1990.
17. Zhai YF, Beittenmiller H, Wang B, et al: Increased expression of specific tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene. Cancer Res 53: 2272-2278, 1993. (Pubitemid 23156812)
18. Paulson JE, Steffensen J-L, Loberg EM, et al: Quantitative and qualitative relationship between displastic aberrant crypt foci and tumorigenesis in the Min/+ mouse colon. Cancer Res 61: 5010-5015, 2001. (Pubitemid 32681528)
19. Saez E, Tontonoz P, Nelson MC, et al: Activators of the nuclear receptor PPAR-γ enhance colon polyp formation. Nat Med 4: 1058-1061, 1998. (Pubitemid 28417339)
20. Min/+ mice. Nat Med 4: 1053-1057, 1998.
21. Min/+ compound mutant mice is linked to premature separation of sister chromatid and enhanced genomic instability. Proc Natl Acad Sci USA 102: 4365-4370, 2005.
22. Beazer-Barclay Y, Levy DB, Moser AR, et al : Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis 17: 1757-1760, 1996. (Pubitemid 26280404)
23. Jacoby RF, Siebert K, Cole CE, et al : The cyclo-oxygenase inhibitor Celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res 60: 5040-5044, 2000.
24. 716mouse by Rofecoxib, a specific cyclo-oxygenase-2 inhibitor. Cancer Res 61: 1733-1740, 2001.
25. 474by a novel COX-2 inhibitor JTE-522. Carcinogenesis 21: 953-958, 2000.
26. Gerner EW and Meyskens FL: Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 4: 785-792, 2004.
27. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82: 241-250, 1999.
28. Perkins S, Verschoyle RD, Hill F, et al : Chemopreventive efficacy and pharmacokinetics of Curcumin in the Min/+ mouse, a model for familial adenomatous polyposis. Cancer Epid Biomark Prev 11: 535-540, 2002. (Pubitemid 34615160)
29. Solomon SD, McMurray JJV, Pfeffer M, et al: Cardiovascular risk associated with Celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071-1080, 2005. (Pubitemid 40365348)
30. Bresalier RS, Sandler RS, Quan H, et al: Cardiovascular events associated with Rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092-1102, 2005. (Pubitemid 40365350)
31. Jacoby RF, Cole CE, Tutsch F, et al: Chemopreventive efficacy of combined piroxicam and difluoro methylornithine treatment on APC mutant Min mouse adenoma and selective toxicity against APC mutant embryos. Cancer Res 60: 1864-1870, 2000. (Pubitemid 30207645)
32. Torrance CJ, Jackson PE, Montgomery E, et al: Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6: 1024-1028, 2000.
33. Swamy MV, Cooma I, Jagan MR, et al: Modulation of COX-2 activity by combined action of celecoxib and docohexaenoic acid. Mol Cancer Ther 3: 215-223, 2004.
34. Ju J, Hong J, Zhou J-N, et al: Inhibition of intestinal tumorigenesis in APC Min/+ mice by (-)-Epigallocatechin-3-Gallate, the major catechin in green tea. Cancer Res 65: 10623-10631, 2005. (Pubitemid 41743758)
35. Khan N, Afaq F, Saleem M, et al: Targeting multiple signaling pathways by green tea polyphenol (-)-Epigallocatechin-3-gallate. Cancer Res 66: 2500-2505, 2006.
36. Yang CS, Maliakal P and Meng X: Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 42: 25-54, 2002. (Pubitemid 34160518)
37. Bharati AC and Aggarwal BB: Nuclear factorκB and cancer: its role in prevention and therapy. Biochem Pharmacol 64: 883-888, 2002.
38. Carothers AM, Moran AE, Cho NL, et al : Changes in antitumor response in C57BL/6J-Min/+ mice during long term administration of a selective cyclo-oxygenase inhibitor. Cancer Res 66: 6432-6438, 2006.
39. Swamy MV, Patlolla JMR, Steele VE, et al: Chemoprevention of familial adenomatous polyposis by low doses of Atorvastatin and Celecoxib given individually and in combination to APCMinmice. Cancer Res 66: 7370-7377, 2006. (Pubitemid 44197721)
40. Polley ACJ, Mulholand F, Pin C, et al : Proteomic analysis reveals field wide changes in protein expression in the morphologically normal colon of patients with colorectal neoplasia. Cancer Res 66: 6553-6562, 2006. (Pubitemid 44085610)
41. Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3: 768-780, 2003.
42. Levi-Ari S, Strier L, Kazanov D, et al: Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res 11: 6738-6744, 2005. (Pubitemid 41339017)
43. Sarkar FH and Li Y: Using chemopreventive agents to enhance the efficacy of cancer chemotherapy. Cancer Res 66: 3347-3350, 2006.
44. Krishnan K, Ruffin MT and Brenner DE: Chemoprevention of colorectal cancer. Crit Rev Oncol 33: 199-219, 2000.
45. Zhu Y, Richardson JA, Parada LF, et al: Smad-3 mutant mice develop metastatic colorectal cancer. Cell 94: 703-714, 1998. (Pubitemid 28436003)
46. Sodir NM, Chen X, Park R, et al: Smad-3 deficiency promotes tumorigenesis in the distal colon of ApcMin/+ mice. Cancer Res 66: 8430-8438, 2006. (Pubitemid 44449154)